However, this expansion seemed to be broader in the tumor microenvironment and was not limited to CD8+ T cells only but included CD4+ T cells, possibly through antigen spreading, despite the lack of an MHC-II-restricted antigen in our vaccine design. This evidence concerns the gene CD4 and neoplasm.